ITP and international guidelines: What do we know, what do we need?

Presse Medicale

Volumn 43, Issue 4P2, 2014, Pages

  Rodeghiero, Francesco ^a   Ruggeri, Marco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; RITUXIMAB; STEROID; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG;

BIOACCUMULATION; BONE MARROW BIOPSY; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RESPONSE; HIGH RISK PATIENT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SPLENECTOMY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INTERNATIONALITY; PRACTICE GUIDELINES AS TOPIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN; SPLENECTOMY; TREATMENT OUTCOME;

EID: 84898912165     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.02.004     Document Type: Short Survey

References (38)

1. George J.N., Woolf S.H., Raskob G.E., Wasser J.S., Aledort L.M., Ballem P.J., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88:3-40.
2. Kojouri K., Vesely S.K., Terrell D.R., George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004, 104:2623-2634.
3. Vesely S.K., Perdue J.J., Rizvi M.A., Terrell D.R., George J.N. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med 2004, 140:112-120.
4. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003, 120:574-596.
5. Arnold D.M., Dentali F., Crowther M.A., Meyer R.M., Cook R.J., Sigouin C., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007, 146:25-33.
6. Bussel J.B., Kuter D.J., George J.N., McMillan R., Aledort L.M., Conklin G.T., et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006, 355:1672-1681.
7. Provan D., Stasi R., Newland A.C., Blanchette V.S., Bolton-Maggs P., Bussel J.B., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
8. Neunert C., Lim W., Crowther M., Cohen A., Solberg L., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
9. Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009, 113:2386-2393.
10. George J.N., Vesely S.K., Woolf S.H. Conflicts of interest and clinical recommendations: comparison of two concurrent clinical practice guidelines for primary immune thrombocytopenia developed by different methods. Am J Med Qual 2014, 29:53-60.
11. Cuker A., Cines D.B. Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia?. Hematology Am Soc Hematol Educ Program 2010, 2010:385-386.
12. Cines D.B., Bussel J.B. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005, 106:2244-2251.
13. Rodeghiero F., Michel M., Gernsheimer T., Ruggeri M., Blanchette V., Bussel J.B., et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood 2013, 121:2596-2606.
14. Khellaf M., Michel M., Schaeffer A., Bierling P., Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005, 90:829-832.
15. Neunert C.E. Current management of immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2013, 2013:276-282.
16. Cheng Y., Wong R.S., Soo Y.O., Chui C.H., Lau F.Y., Chan N.P., et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003, 349:831-836.
17. Mazzucconi M.G., Fazi P., Bernasconi S., De Rossi G., Leone G., Gugliotta L., et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007, 109:1401-1407.
18. Arnold D.M., Heddle N.M., Carruthers J., Cook D.J., Crowther M.A., Meyer R.M., et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood 2012, 119:1356-1362.
19. Sailer T., Lechner K., Panzer S., Kyrle P.A., Pabinger I. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006, 91:1041-1045.
20. Rodrigo C., Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost 2013, 11:1946-1953.
21. Maloisel F., Andres E., Zimmer J., Noel E., Zamfir A., Koumarianou A., et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 2004, 116:590-594.
22. Kuter D.J., Bussel J.B., Newland A., Baker R.I., Lyons R.M., Wasser J., et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013, 161:411-423.
23. Saleh M.N., Bussel J.B., Cheng G., Meyer O., Bailey C.K., Arning M., et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013, 121:537-545.
24. Rodeghiero F., Stasi R., Giagounidis A., Viallard J.F., Godeau B., Pabinger I., et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol 2013, [Epub ahead of print]. 10.1111/ejh.12181.
25. Ghadaki B., Nazi I., Kelton J.G., Arnold D.M. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013, [Epub ahead of print]. 10.1111/trf.12139.
26. Bao W., Bussel J.B., Heck S., He W., Karpoff M., Boulad N., et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010, 116:4639-4645.
27. George J.N. Management of immune thrombocytopenia-something old, something new. N Engl J Med 2010, 363:1959-1961.
28. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012, 120:960-969.
29. Portielje J.E., Westendorp R.G., Kluin-Nelemans H.C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001, 97:2549-2554.
30. McMillan R., Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004, 104:956-960.
31. Vianelli N., Palandri F., Polverelli N., Stasi R., Joelsson J., Johansson E., et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow-up of 10 years. Haematologica 2013, 98:875-880.
32. Ruggeri M., Tosetto A., Palandri F., Polverelli N., Mazzucconi M.G., Santoro C., et al. Personal and treatment-related risk factors explain a slightly increased thrombotic risk in patients with primary immune thrombocytopenia. J Thromb Haemost 2014, [Submitted].
33. Boyle S., White R.H., Brunson A., Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013, 121:4782-4790.
34. Zeng Y., Duan X., Xu J., Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011, 7. [CD008235].
35. Rodeghiero F. TPO-receptor agonists in ITP: a clinician's navigation between Scylla and Charybdis. Am J Hematol 2012, 87:943.
36. Pignatti F., Flores B., Jonsson B. Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective. Am J Hematol 2012, 87:943-944.
37. Arnold D.M. Platelet count or bleeding as the outcome in ITP trials?. Am J Hematol 2012, 87:945-946.
38. Ruggeri M. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective. Am J Hematol 2012, 87:946-947.